On this page
Dabur, Ferns N Petals and Lotte India correct labelling and advertising lapses after FSSAI notices
Our read
FSSAI scrutiny pushes FMCG brands into a broader claims-and-classification cleanup, increasing compliance costs while reducing aggressive health-led marketing.
For operators
FSSAI enforcement raises the compliance bar for FMCG operators, making label governance, product classification and substantiated advertising claims operational priorities.
Watch
Additional FSSAI notices, penalties, product withdrawals, or public naming of brands in adjacent FMCG categories.
The report,
FSSAI said Dabur, Ferns N Petals and Lotte India corrected labelling, classification and advertising lapses after regulatory notices. Actions included relisting Dabur oil as Ayurvedic medicine, revised chocolate labels, and removal or correction of product claims.
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
Reported figures
From the report. Source details below
- 100%
Why it matters to operators and investors
Acquirers should intensify regulatory diligence on product classifications, packaging claims and advertising substantiation before valuing FMCG targets.
What to watch next
- Formal FSSAI guidance on classification boundaries between food products, nutraceuticals, Ayurvedic medicines, and cosmetic or personal-care products.
- Advertising Standards Council of India actions against health, immunity, therapeutic, or misleading natural-product claims.
- Rising frequency of packaging changes, e-commerce listing edits, or discontinued SKUs among consumer brands.
- Consumer complaints, retailer queries, or social-media scrutiny linking claim corrections to product safety or efficacy concerns.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Audit product classifications, ingredient declarations, mandatory label disclosures, and substantiation files for all health, wellness, natural, immunity, digestive, and therapeutic claims.
- Pause or revise ambiguous advertising copy across packaging, e-commerce listings, quick-commerce product pages, social media, and influencer briefs.
- Prepare relabelling inventory plans to minimize write-offs and retailer delistings if packaging changes are mandated.
- Increase legal-regulatory review of products positioned between food, supplements, Ayurvedic medicine, and cosmetics.
- Use corrected claims to build a compliance narrative with trade partners and consumers before competitors frame the issue as a trust deficit.
The counter-case
The case against this reading — not reported by the source.
The notices may be isolated, already-remediated compliance issues rather than evidence of a sector-wide tightening that materially affects sales, margins or brand trust. Prompt label and claim corrections can limit enforcement exposure, while Dabur’s reclassification of an oil product as an Ayurvedic medicine may shift regulatory treatment rather than indicate a product-quality failure. Without fines, recalls, sales restrictions or repeat violations, the commercial impact could be negligible.
The source
Published
First seen